Physician profile
Michael Mccormick
NPI 1235215302
$1,028.38
in general payments reported to CMS, 2019-2025
15 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.21 · 2020: $108 · 2021: $62.11 · 2022: $164 · 2023: $203 · 2024: $270 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $260.67 | 2020-2025 | Nucala, Trelegy Ellipta |
| Optinose US, INC. | $126.02 | 2019-2024 | |
| Grifols USA, LLC | $70.78 | 2023-2025 | Xembify |
| Genzyme Corporation | $68.96 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $63.77 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $60.78 | 2022-2024 | Airsupra |
| Amgen INC. | $59.27 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $55.68 | 2024-2025 | Orladeyo |
| Blueprint Medicines Corporation | $52.17 | 2024 | Ayvakit |
| Greer Laboratories, INC. | $51.18 | 2020-2023 | Oralair |
| Pfizer INC. | $39.80 | 2022-2024 | |
| Leo Pharma INC. | $39.15 | 2022-2023 | Adbry |
| Abbvie INC. | $32.95 | 2024 | |
| Mylan Specialty L.P. | $25.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mccormick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.